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Analysis of mitochondrial function 
in human induced pluripotent 
stem cells from patients with 
mitochondrial diabetes due to the 
A3243G mutation
Masaki Matsubara1,2, Hajime Kanda1, Hiromi Imamura  3, Mayumi Inoue1,2, Michio Noguchi1, 
Kiminori Hosoda4, Akira Kakizuka3 & Kazuwa Nakao1
We previously established human induced pluripotent stem (iPS) cells in two diabetic patients from 
different families with the mitochondrial A3243G mutation and isolated isogenic iPS cell clones with 
either undetectable or high levels of the mutation in both patients. In the present study, we analyzed 
the mitochondrial functions of two mutation-undetectable and two mutation-high clones in each 
patient through four methods to assess complex I activity, mitochondrial membrane potential, 
mitochondrial respiration, and mitochondrial ATP production. In the first patient, complex I activity, 
mitochondrial respiration, and mitochondrial ATP production were decreased in the mutation-high 
clones compared with the mutation-undetectable clones, and mitochondrial membrane potential 
was decreased in a mutation-high clone compared with a mutation-undetectable clone. In the second 
patient, complex I activity was decreased in one mutation-high clone compared with the other clones. 
The other parameters showed no differences in any clones. In addition, the complex I activity and 
mitochondrial respiration of the mutation-undetectable clones from both patients were located in the 
range of those of iPS cells from healthy subjects. The present study suggests that the mitochondrial 
function of the mutation-undetectable iPS cell clones obtained from two patients with the A3243G 
mutation is comparable to the control iPS cells.
Like embryonic stem (ES) cells, human induced pluripotent stem (iPS) cells, which are generated from 
somatic cells, possess pluripotency in all three germ layers; therefore, they are considered promising sources 
for cell-replacement therapy and useful tools for developing disease models or drug screening1,2. Recently, iPS 
cell-derived retinal pigment epithelial cells were transplanted to a patient with neovascular age-related macular 
degeneration and no serious events were observed at two years of follow-up3. Although a major concern about 
cell replacement therapy is tumorigenicity4, integration-free methods to generate iPS cells5, in vivo tumorigenicity 
tests6, and precise assessments of genome integrity3 could prevent tumorigenesis. Mitochondria contain their own 
genomes, known as mitochondrial DNA (mtDNA), and mtDNA mutations induce mitochondrial dysfunction, 
thereby causing mitochondrial diseases. An A to G mutation at position 3243 (A3243G) in the mitochondrial 
tRNALeu(UUR) gene is one of the most frequent mtDNA mutations7. It is associated with various clinical symptoms, 
such as diabetes mellitus, hearing loss, and cardiomyopathy, and found in approximately 80% of patients with 
mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS)8–11.
Previously, we established human iPS cell lines in two patients from different families carrying the mtDNA 
A3243G mutation (Mt iPS cells): patient 1 (Pt1) was diabetic, and patient 2 (Pt2) had diabetes and MELAS12. A 
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striking feature of Mt iPS cells is that mtDNA mutation frequencies decrease to undetectable levels in approx-
imately half of the clones while they increase to more than 70% in the other half of the clones; this effect is 
observed in both patients. We speculate that two separate types of iPS cells, namely, mutation-undetectable 
clones (less than 2%) and mutation-high clones (more than 70%), arise through the process of iPS cell generation. 
Following our discovery, several studies have also reported that mutation-undetectable iPS cells can be generated 
in the process of reprograming, probably led by bimodal segregation toward homoplasmy, from patients carrying 
mtDNA mutations, thus suggesting a common mechanism for mitochondrial diseases13–16.
The mitochondrial function of the mutation-undetectable Mt iPS cell clones remains to be elucidated. It is 
unclear whether the mitochondrial function is different between the mutation-undetectable Mt iPS cell clones 
and the iPS cells from healthy subjects. In the present study, we analyzed the mitochondrial function of the Mt 
iPS cell clones, three control iPS cell lines from healthy subjects, and one ES cell line with regard to the following 
four parameters: complex I activity, mitochondrial membrane potential, oxygen consumption rate (OCR), and 
cytosolic ATP concentration.
Results
Complex I activity analyzed via colorimetric assay. The complex I activity of iPS cells from Pt1 (Mt1 
iPS cells) was decreased in the mutation-high clones, designated by a superscript ‘high’, compared with the muta-
tion-undetectable clones, designated by a superscript ‘low’. The enzymatic activities of complex I were 102.2% 
(Mt1-2low), 63.4% (Mt1-3high), and 47.2% (Mt1-4high) of the activity of Mt1-1low (calculated as a percentage of 
Mt1-1low; Fig. 1a, n = 5–8). The complex I activity of Mt1-3high and Mt1-4high was statistically significantly lower 
than that of Mt1-1low and Mt1-2low. The complex I activity of iPS cells from Pt2 (Mt2 iPS cells) was decreased 
in Mt2-5high, which had the highest mutation frequency (85%), compared with the other clones. The complex 
I activities of the Mt2 iPS cell clones were 83.6% (Mt2-8low), 88.5% (Mt2-6high), and 38.9% (Mt2-5high) of that 
found in Mt2-3low (Fig. 1b, n = 5–6). The complex I activity of Mt2-5high was statistically significantly lower than 
that of Mt2-3low, Mt2-8low, and Mt2-6high. The complex I activity among Mt2-3low, Mt2-8low, and Mt2-6high was not 
statistically significantly different. Moreover, the complex I activity of the three iPS cell lines (B71, W1217, and 
TIG10718) generated from healthy subjects and the ES cell line (KhES-119) were compared with that of the muta-
tion-undetectable Mt iPS cell clones (Mt1-1low and Mt2-3low) and the complex I activity was comparable between 
the mutation-undetectable Mt iPS cell clones and the control pluripotent stem cells (PSCs) (Supplementary Fig. 1, 
n = 10–15).
Mitochondrial membrane potential analyzed with fluorescence-activated cell sorting 
(FACS). MitoTracker Green and tetramethylrhodamine, ethyl ester, perchlorate (TMRE) intensity showed 
that in the basal state, the mutation-undetectable clones and the mutation-high clones did not show different 
peak positions among the Mt1 and Mt2 iPS cell clones (data not shown). The TMRE peak position of the Mt iPS 
cells shifted to the left after treatment with 4 μM carbonyl cyanide 4-trifluoromethoxy-phenylhydrazone (FCCP). 
Among the Mt1 iPS cell clones, the intensity of the TMRE peaks were decreased to 78.4% (Mt1-1low), 46.9% (Mt1-
2low), 39.5% (Mt1-3high), and 16.6% (Mt1-4high) after FCCP administration shown in histograms with the horizon-
tal axis as the fluorescence intensity and the vertical axis as the percentage of cells (Fig. 2a,b,c and d, n = 4). The 
TMRE peak after FCCP treatment was statistically significantly lower in Mt1-4high than in Mt1-1low. However, the 
TMRE peaks were decreased to 34.6% (Mt2-3low), 65.9% (Mt2-8low), 26.4% (Mt2-6high), and 38.3% (Mt2-5high) 
after FCCP administration; the peak decrease was not statistically significantly different among the Mt2 iPS cell 
clones (Fig. 2e,f,g and h, n = 3).
Figure 1. Complex I activity of the Mt iPS cell clones. The complex I activity of the Mt iPS cell clones was 
analyzed. The data of the Mt1 iPS cell clones (a) were normalized to Mt1-1low, and those of the Mt2 iPS cell 
clones (b) were normalized to Mt2-3low. The data are expressed as the means ± SE. n = 5–8. **P < 0.01, ANOVA 
with a post hoc test (Tukey’s test).
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Oxygen consumption rate measured using an extracellular flux analyzer. OCR was measured 
using a series of mitochondria-specific inhibitors or a respiration uncoupling reagent to determine the bioen-
ergetic profiles of the iPS cells. This sequence provides the following profiles of mitochondrial activity:(1) basal 
respiration;(2) the component of OCR used for ATP production, which is the difference between the basal OCR 
and the oligomycin A-repressed OCR;(3) the component of OCR representing proton leak across the mito-
chondrial inner membrane, which is the difference between the oligomycin A-repressed OCR and the rotenone 
plus antimycin A-inhibited OCR; and (4) the spare respiratory capacity, which is the difference between the 
FCCP-induced OCR and the basal OCR (Supplementary Fig. 2).
The representative time course data for the Mt1 iPS cell clones (n = 4–5) and the Mt2 iPS cell clones (n = 4–5) 
are shown in Fig. 3a and b, respectively. On the basis of flux analysis among the Mt1 iPS cell clones, the basal res-
piration, ATP production, and spare respiratory capacity were decreased in the mutation-high clones compared 
with the mutation-undetectable clones. The basal respiration of Mt1-2low, Mt1-3high, and Mt1-4high was 91.8%, 
72.2%, and 53.8% of that of Mt1-1low, respectively. The basal respiration of Mt1-4high was statistically significantly 
lower than that of Mt1-1low and Mt1-2low, and that of Mt1-3high was statistically significantly lower than that of 
Mt1-1low (Fig. 3c). The ATP production of Mt1-2low, Mt1-3high, and Mt1-4high was 93.3%, 71.6%, and 28.9% of that 
of Mt1-1low, respectively. The ATP production of Mt1-4high was statistically significantly lower than that of Mt1-
1low, Mt1-2low, and Mt1-3high, whereas the ATP production of Mt1-3high was statistically significantly lower than 
that of Mt1-1low and Mt1-2low (Fig. 3d). The spare respiratory capacity of Mt1-2low, Mt1-3high, and Mt1-4high was 
88.8%, 67.7%, and 25.8% of that of Mt1-1low, respectively. The spare respiratory capacity of Mt1-4high was statis-
tically significantly lower than that of Mt1-1low and Mt1-2low (Fig. 3e). The proton leak did not show statistically 
significant difference (Fig. 3f).
Among the Mt2 iPS cell clones, basal respiration, ATP production, spare respiratory capacity, and proton 
leak were not different, even in the clone with the highest mtDNA mutation frequency (Mt2-5high). The basal 
respiration of Mt2-8low, Mt2-6high, and Mt2-5high was 104.4%, 108.4%, and 116.7% of that of Mt2-3low, respectively 
Figure 2. Mitochondrial membrane potential of the Mt iPS cell clones, as measured by FACS analysis. 
Representative histograms of TMRE intensity among the Mt1 iPS cell clones ((a): 1-1low, (b): 1-2low, (c): 1-3high, 
(d): 1-4high) and the Mt2 iPS cell clones ((e): 2-3low, (f): 2-8low, (g): 2-6high, (h): 2-5high) are shown. The Mt iPS cells 
were treated with 4 μM FCCP or DMSO for 10 min and analyzed independently. The TMRE peak decreased 
after FCCP administration was statistically significantly lower in Mt1-4high than in Mt1-1low among the Mt1 
iPS cell clones, while it was not statistically significantly different among the Mt2 iPS cell clones assessed using 
ANOVA with a post hoc test (Tukey’s test).
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(Fig. 3g). The ATP production of Mt2-8low, Mt2-6high, and Mt2-5high was 106.3%, 117.3%, and 115.4% of that of 
Mt2-3low, respectively (Fig. 3h). The spare respiratory capacity of Mt2-8low, Mt2-6high, and Mt2-5high was 107.6%, 
85.1%, and 99.9% of that of Mt2-3low, respectively (Fig. 3i). Furthermore, the control PSCs (B7, W12, TIG107, 
and KhES-1) were compared with Mt1-1low and Mt2-3low. The basal respiration, ATP production, and spare res-
piratory capacity of the mutation-undetectable Mt iPS cell clones from both patients were comparable to those 
of the control PSCs (Supplementary Fig. 3, n = 8–9). The analysis was performed independently three times for 
all sets of cells.
Dynamics of cytosolic ATP concentration. The cytosolic ATP concentration was measured using fluo-
rescence resonance energy transfer (FRET)-based ATP biosensor ATeam 1.0320. The A3243G mutation frequen-
cies of the Mt iPS cells with stable genomic integration of ATeam 1.03 (ATeam-iPS cells) were evaluated with the 
Invader assay21; the results showed that the mutation frequencies were not influenced by genomic integration 
of ATeam 1.03 (Supplementary Fig. 4). The time course and sequential images of the FRET signal (yellow flu-
orescent protein [YFP]/cyan fluorescent protein [CFP] ratio) are shown in a single Mt1-1low iPS cell expressing 
ATeam 1.03 after the injection of 2-deoxy-D-glucose (2DG) (Fig. 4a,b). Before the injection of 2DG or oligo-
mycin A (representing the basal ATP concentration), the FRET signals of the Mt1 and Mt2 iPS cell clones were 
not statistically significantly different. Mitochondrial oxidative phosphorylation (OXPHOS)-dependent and 
glycolysis-dependent ATP production, respectively, were detected by injecting 2DG or oligomycin A and obtain-
ing sequential FRET signal. The injection of oligomycin A had little effect on the ATP levels between both the Mt1 
and Mt2 iPS cell clones (Fig. 4c,d, n = 10–14). Among the Mt1 iPS cell clones, OXPHOS-dependent ATP produc-
tion, analyzed via 2DG, was decreased in the mutation-high clones compared with the mutation-undetectable 
clones. After the injection of 2DG, FRET signals (YFP/CFP ratio) of 71.5% (Mt1-1low), 77.2% (Mt1-2low), 65.1% 
(Mt1-3high), and 63.0% (Mt1-4high) were observed compared with the basal condition; the FRET signals of Mt1-
3high and Mt1-4high were statistically significantly lower than those of Mt1-1low and Mt1-2low (Fig. 4e, n = 11–16). 
Among the Mt2 iPS cell clones, mitochondrial ATP production were not different. FRET signals were observed 
at 70.6% (Mt2-3low), 74.9% (Mt2-8low), 73.7% (Mt2-6high), and 72.9% (Mt2-5high) after the injection of 2DG; there 
were no statistically significant differences (Fig. 4f, n = 11–16). The FRET signals before and after 2DG injec-
tion showed statistically significant difference in each clone among the Mt iPS cells (P < 0.01, Student’s t-test) 
(Fig. 4e,f).
Discussion
In the present study, the complex I activity, mitochondrial membrane potential, mitochondrial respiration, and 
mitochondrial ATP production were analyzed among two mutation-undetectable and two mutation-high Mt 
iPS cell clones from two patients with the A3243G mutation of different pedigrees. In addition, the complex I 
activity and mitochondrial respiration of the mutation-undetectable Mt iPS cell clones from both patients were 
compared with those of the control PSCs. The present study shows the following observations: (1) among the 
Mt1 iPS cell clones, the complex I activity, OCR (contributed to by basal respiration, ATP production, and spare 
respiratory capacity) and mitochondrial ATP production were decreased in the mutation-high clones compared 
with the mutation-undetectable clones. Mitochondrial membrane potential after FCCP treatment was decreased 
Figure 3. The oxygen consumption rate (OCR) of the Mt iPS cell clones measured using an XF96 Extracellular 
Flux Analyzer. Representative data for the Mt1 iPS cell clones are shown as follows: (a) time course (open circle, 
Mt1-1low; open square, Mt1-2low; closed circle, Mt1-3high; closed square, Mt1-4high), (c) basal OCR, (d) ATP 
production, (e) spare respiratory capacity, and (f) proton leak. Representative data for the Mt2 iPS cell clones are 
shown as follows: (b) time course (open circle, Mt2-3low; open square, Mt2-8low; closed square, Mt2-6high; closed 
circle, Mt2-5high), (g) basal OCR, (h) ATP production, (i) spare respiratory capacity, and (j) proton leak. OCR 
was normalized to total protein and is expressed as the mean ± SD. n = 4–5. **P < 0.01 and *P < 0.05, ANOVA 
with a post hoc test (Tukey’s test).
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in the clone with the highest mtDNA mutation frequency compared with one of the mutation-undetectable 
clones; (2) among the Mt2 iPS cell clones, the complex I activity was decreased in the clone with the highest 
mtDNA mutation frequency compared with the other clones, whereas the parameters assessed using FACS, 
extracellular flux analysis, and ATeam 1.03 showed no differences among any of the clones; (3) the complex I 
activity and OCR (contributed to by basal respiration, ATP production, and spare respiratory capacity) of the 
mutation-undetectable Mt iPS cell clones (Mt1-1low and Mt2-3low) were comparable to those of the control PSCs. 
Taken together, the present study suggests that the mitochondrial function of the mutation-undetectable clones 
is higher than that of the mutation-high clones in Pt1. In addition, the results suggest that the mitochondrial 
function of the mutation-undetectable clones from both patients is comparable to that of the control iPS cells. 
This study is the first to our knowledge to analyze the mitochondrial function, via a variety of assays, of iPS cells 
derived from two genetically unrelated patients with the A3243G mutation.
Mitochondria generate ATP via OXPHOS, which is driven by the electron transport chain (ETC)22. The ETC 
consists of five sequential multiprotein complexes, I (NADH ubiquinone reductase), II (succinate ubiquinone 
reductase), III (ubiquinol cytochrome C reductase), IV (cytochrome oxidase), and V (ATP synthase); oxygen is 
reduced to water by complex IV, and ATP is finally produced by complex V22. Complexes I, III, IV, and V are com-
posed of subunits encoded in both mtDNA and the nuclear genome, and complex II consists of subunits encoded 
only in the nuclear genome22. A3243G is a point mutation in the mitochondrial tRNALeu(UUR) gene that causes a 
respiratory defect chiefly due to a deficiency of complex I. Regarding the mechanism of complex I deficiency in 
patients with the A3243G mutation, abnormal tRNA conformation23, lack of 3′-end processing, CCA addition24, 
aminoacylation25,26, transcription termination27, and/or 5-taurinomethyluridine modification28,29 are considered 
to cause insufficient translation of leucine. Our findings on decreased complex I activity in mutation-high iPS cell 
clones are consistent with the results of previous reports23–29.
In Pt2, complex I activity was decreased in Mt2-5high (mutation frequency: 85%), but not in Mt2-6high (muta-
tion frequency: 70%). We speculate a threshold effect of mitochondrial heteroplasmy, which was reported using 
the cytoplasmic hybrid, or cybrid, method30. In typical cases of pathogenic mitochondrial tRNA mutations, when 
the proportion of mutant mtDNA is lower than 85% to 90%, the cell maintains its normal physiological function 
and phenotype30. After the ratio of mutant mtDNA exceeds the threshold value, the energetic biological capacity, 
such as complex I activity in this case, is impaired30. Our results suggest that the threshold value to maintain com-
plex I activity is between 70% and 85% among the Mt2 iPS cells.
In Mt2-5high, the mitochondrial membrane potential after treatment with FCCP, mitochondrial respiration 
and mitochondrial ATP production were not different from those of the other Mt2 iPS cell clones, though the 
complex I activity was decreased. We speculate that a common molecular mechanism, which depends on the 
A3243G mutation, can decrease the mitochondrial function assessed in the present study. Therefore, a compen-
satory mechanism could maintain the normal functioning of mitochondrial OXPHOS in Mt2-5high. In previous 
studies, some mtDNA mutations, including position 3243 mutations, have been found to be accompanied by 
Figure 4. Time-lapse imaging of the Mt iPS cell clones expressing ATeam1.03, a FRET-based ATP biosensor. 
The time course of the YFP/CFP emission ratio (a) and the sequential images (b) in a single iPS cell of Mt1-1low 
expressing ATeam 1.03 were examined after injection of 2DG. 2DG was injected at 10 min. The representative 
data are expressed as the means ± SD. n = 6 (Scale bar, 10 μm). The YFP/CFP emission ratio of the Mt1 iPS cell 
clones (c) and the Mt2 iPS cell clones (d) at 10 min (before the oligomycin A injection) and 30 min (20 min after 
the oligomycin A injection) was measured. The YFP/CFP emission ratio of the Mt1 iPS cell clones (e) and the 
Mt2 iPS cell clones (f) at 10 min (before 2DG injection) and 40 min (30 min after 2DG injection) was measured. 
The data are expressed as the means ± SE. n = 10–14 (c) (d). n = 11–16 (e) (f). **P < 0.01 and *P < 0.05, among 
the 2DG groups assessed by ANOVA with a post hoc test (Tukey’s test). #P < 0.01, compared with basal for each 
clone assessed using the Student’s t-test.
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downregulation of complex I but upregulation of complexes II, III, and IV13,31,32. The counter-regulation of com-
plexes II–IV may contribute to the ability of Mt2-5high to maintain normal mitochondrial function. Regarding 
Pt1, although the compensatory mechanism supporting normal mitochondrial function should work in the 
mutation-high iPS cell clones, the A3243G mutation strongly decreased mitochondrial function beyond the 
capacity of the compensatory mechanism. The difference in mitochondrial function between the Mt1 and Mt2 iPS 
cells may be explained by the unique nuclear genome information of each patient; that is, the genome background 
of each patient may contribute to the compensatory capacity to a certain degree. It is highly likely that the mito-
chondrial function of the Mt iPS cells is dependent on their genomic background, in addition to heteroplasmy 
and the threshold effect.
The mutation-undetectable iPS cell clones should be very important for cell replacement therapy if their mito-
chondrial function is comparable to iPS cells from healthy subjects. For this reason, the mitochondrial function 
of the mutation-undetectable Mt iPS cell clones (Mt1-1low and Mt2-3low) was compared with three control iPS 
cell lines and one ES cell line (Supplementary Fig. 1, 3). Complex I activity and mitochondrial respiration were 
assessed, and the results showed that the complex I activity and OCR (contributed to by basal respiration, ATP 
production, and spare respiratory capacity) were comparable between the mutation-undetectable Mt iPS cell 
clones and the control PSCs. These results suggest that the mitochondrial function of the mutation-undetectable 
Mt iPS cell clones is comparable to the control iPS cells.
A recent study on mitochondria in PSCs reported that these cells contain immature and inactive mitochon-
dria, while still possessing functional respiratory complexes, and rely heavily on anaerobic glycolysis compared 
with somatic cells33–36. In the present study, the ATP production of OXPHOS (Fig. 4e,f) was much lower than 
that of glycolysis (Fig. 4c,d) in all Mt iPS cell clones, and these results are consistent with previous studies33–36. 
According to previous reports33–36, identification of mitochondrial functional defects could be more difficult 
in iPS cells with mitochondrial mutations than in somatic cells because the mitochondrial functions of the 
mutation-high and the mutation-undetectable clones may not be significantly different in the stem cell state. 
The present study demonstrates that the four methods used in this study could be useful to assess differences in 
mitochondrial function caused by the A3243G mutation in iPS cells.
Patients with mitochondrial A3243G mutations present with various types of clinical phenotypes. In the cur-
rent study, the clinical features of Pt1 and Pt2 were markedly different: the former showed only diabetes, while the 
latter showed diabetes and MELAS. We speculate that the mutation frequency in neurons and cardiomyocytes 
might be much higher in Pt2 than in Pt1. Regarding the diabetic phenotype, both patients had insulin-dependent 
diabetes mellitus with a similar severity of insufficient insulin secretion in their thirties. In terms of diabetes, the 
following factors, which are involved in the pathological mechanisms of the disease, should be carefully consid-
ered. (1) Heteroplasmy: organ function in mitochondrial diseases strongly relies on mitochondrial heteroplasmy 
in the somatic cells of the affected tissues. Although the fibroblasts obtained from skin biopsies in the two patients 
showed comparable mutation frequencies (18%: Pt1, 24%: Pt2), the heteroplasmy of beta cells may be different. 
The degree of heteroplasmy is unknown in both patients, because clinical limitations make sampling of beta cells 
difficult. (2) Lifestyle factors: dietary habits, exercise, and various environmental-related factors strongly affect 
the clinical course of diabetes. (3) Nuclear genome background: genetic factors, in addition to mtDNA mutation, 
also affect the onset or progression of diabetes. Therefore, the clinical aspects of diabetes should be carefully con-
sidered in both patients.
It is crucial for regenerative medicine to clarify whether iPS cells have the potential to differentiate into 
tissue-specific cells. We have previously reported the capability of ES cells and iPS cells to differentiate into 
vascular endothelial cells37–40, adipocytes17,18,41, steroid-producing cells42, and chondrocytes43. In patients with 
mitochondrial diabetes, beta cells cannot satisfy the energetic or signaling requirements for glucose-stimulated 
insulin secretion, owing to impaired ETC function in the mitochondria44. Thus, pancreatic beta cells gener-
ated from PSCs possessing normal mitochondrial function are an essential resource for cell replacement ther-
apy for mitochondrial diabetes. Recently, two different research groups have differentiated human PSCs into 
insulin-containing cells expressing beta cell transcription factors; in addition, glucose-stimulated insulin secre-
tion in vitro and reversal of hyperglycemia in diabetic mice after transplantation have been reported45,46.
Several studies have also reported that mutation-undetectable iPS cells are generated from patients with the 
A3243G mutation, as demonstrated in our previous study12,13,16. Given these previous reports, it is highly probable 
that mutation-undetectable iPS cells can be generated from the fibroblasts of any patients with the mitochondrial 
A3243G mutation. The present study of iPS cells from two patients suggests that the mitochondrial function 
of the mutation-undetectable iPS cell clones is comparable to that of the control iPS cells. The results also sug-
gest that the same phenomenon could be present in mutation-undetectable iPS cells established from almost all 
patients with the A3243G mutation. This phenomenon highlights the potential of this approach in the future 
development of autologous cell replacement therapy for patients with the mitochondrial A3243G mutation.
In summary, we established isogenic iPS cells with undetectable levels or high levels of mtDNA mutation from 
two diabetic patients with the A3243G mutation. The present study suggests that the mitochondrial function of 
the mutation-undetectable iPS cell clones is comparable to that of the control iPS cells. After the development of 
appropriate and safe methods for the differentiation of iPS cells into beta cells in the future, our approach to gen-
erating mutation-undetectable iPS cells holds promise in the development of autologous cell replacement therapy 
for patients with mitochondrial diabetes due to the A3243G mutation.
Materials and Methods
Patient information. Pt1 was a 38-year-old male with a family history of MELAS. His mother had diabe-
tes mellitus, cardiomyopathy, and hearing loss. He was hospitalized because of severe weight loss, hydrodipsia, 
and polyuria when he was 30 years old. He was given a diagnosis of insulin-dependent diabetes mellitus and 
treated with insulin therapy. Pt2 was a 46-year-old female who had diabetes mellitus, hearing loss, epilepsy, and 
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cardiomyopathy. She was diagnosed with gestational diabetes mellitus during her first pregnancy, when she was 
24 years old. She was treated with insulin therapy for diabetic ketoacidosis when she was 31 years old. She was 
hospitalized repeatedly because of epilepsy and acute exacerbation of chronic heart failure.
iPS cell clones. Several iPS cell lines were generated from Pt1 (Mt1 iPS cells) and Pt2 (Mt2 iPS cells) using a 
retrovirus encoding OCT4, SOX2, c-MYC, and KLF4. These iPS cell clones had normal karyotypes and met pluri-
potency criteria12. The A3243G mutation frequencies of the Mt iPS cell clones were evaluated by using the Invader 
assay21. An analysis of the same clones at various passage numbers revealed that no induction of the mutation 
occurred in the mutation-undetectable Mt iPS cell clones and that the mutation frequencies of the mutation-high 
Mt iPS cell clones were relatively constant across passages12. Moreover, the mtDNA content of the Mt iPS cells 
after passage 20 was similar to that of human ES cells12. The following eight clones from the Mt1 and Mt2 iPS cells 
were selected and used at passage 20–40 in further analyses: two mutation-undetectable clones (Mt1-1low, Mt1-
2low) and two mutation-high clones (mtA3243G mutation frequencies of 77% [Mt1-3high] and 91% [Mt1-4high]) 
from the Mt1 iPS cells; and two mutation-undetectable clones (Mt2-3low, Mt2-8low), which were randomly selected 
from among six mutation-undetectable clones, and two mutation-high clones (mtA3243G mutation frequencies 
of 70% [Mt2-6high] and 85% [Mt2-5high]), which were selected because they possessed the lowest and highest 
mutation frequencies, respectively, among the four mutation-high clones, from the Mt2 iPS cells. The clone num-
ber of the Mt iPS cells was based on a previous report12. In addition, three iPS cell lines (B7, W12, and TIG107) 
and one ES cell line (KhES-1) were used as controls.
Cell culture. Mitochondrial diabetes-specific iPS cells were cultured on mitomycin C (Sigma-Aldrich, St. 
Louis, MO, USA)-treated mouse embryonic fibroblast cell line (SNL) cells47 by using primate ES cell medium 
(ReproCELL, Yokohama, Japan) supplemented with 4 ng/ml of basic fibroblast growth factor (Wako, Osaka, 
Japan). The culture medium was changed every day. The iPS cells were passaged every 5–7 days after removal of 
the feeder cells using 0.25% trypsin (Nacalai Tesque, Kyoto, Japan) with 0.1 mg/ml collagenase type IV (Thermo 
Fisher Scientific, Waltham, MA, USA) and 20% KnockOut Serum Replacement (Thermo Fisher Scientific). 
After removal of the mouse feeder cells, the iPS cells were incubated in Accumax (Funakoshi, Tokyo, Japan) for 
10 min and dissociated into single cells. Single iPS cells were seeded on growth-factor-reduced Matrigel (#356231; 
Corning, New York, NY, USA)-coated dishes using mTeSR1 medium (STEMCELL Technologies, Vancouver, 
Canada) supplemented with 10 μM Y-273652 (Nacalai Tesque).
Measurement of complex I activity. The activity of complex I was measured using a Complex I Enzyme 
Activity Microplate Assay Kit (ab109721; Abcam, Cambridge, MA, USA) according to the manufacturer’s proto-
col. Briefly, protein was extracted from iPS cells using the detergent provided by the manufacturer. The protein 
concentration was measured using DC Protein Assay Reagent (BIO-RAD, Hercules, CA, USA), and all samples 
were diluted to the manufacturer-recommended concentration. Equal amounts of each sample were loaded onto 
the plate and incubated for 3 hours at room temperature. After incubation, NADH and dye provided by the man-
ufacturer were loaded onto the plate, and the absorbance at 450 nm in each well was measured at 1-min intervals 
for 30 min. The linear rate of increase in absorbance at 450 nm was calculated.
FACS analysis. FACS analysis was performed to evaluate the significance of the A3243G mutation by using 
two types of mitochondria-specific labels. MitoTracker Green (Thermo Fisher Scientific) and TMRE (Thermo 
Fisher Scientific), respectively, to distinguish total mitochondrial mass and respiration. The iPS cells were incu-
bated with 100 nM MitoTracker Green and 50 nM TMRE at 37 °C for 15 min. The iPS cells were dissociated 
into single cells as described above, collected in Hank’s balanced salt solution (HBSS) medium (Thermo Fisher 
Scientific) supplemented with 2% FBS (Sigma-Aldrich), and analyzed using flow cytometry (LSRFortessa Cell 
Analyzer; BD Biosciences, San Jose, CA, USA). Next, FCCP (Sigma-Aldrich), a respiratory uncoupler, was added 
to a final concentration of 4 μM. Data were analyzed using FlowJo software (Treestar, Ashland, OR, USA).
Extracellular flux analysis. The OCR was measured using an XF96 Extracellular Flux Analyzer (Seahorse 
Bioscience, Billerica, MA, USA) according to the manufacturer’s protocol. The iPS cells were dissociated into 
single cells as described above, and 4 × 104 cells were seeded onto an XF96 cell-culture microplate coated with 
Matrigel using mTeSR1 medium containing 10 μM compound Y-27632. The next day, the medium was replaced 
with XF assay medium48, followed by sequential injection of 2 μM oligomycin A, 62.5 nM FCCP, 10 mM antimy-
cin A (Sigma-Aldrich), and 10 mM rotenone (Sigma-Aldrich). The results were normalized to the total protein 
content in each well, which was determined using DC Protein Assay Reagent.
Generation of a stable iPS cell line (ATeam-iPS cells). The use of the previously developed ATeam 
1.03 allowed for direct monitoring of cytosolic ATP levels in a single living cell20. Briefly, genetically encoded ATP 
biosensor ATeam 1.03 is based on the principle of FRET and is specific for ATP. It is composed of the epsilon sub-
unit of Bacillus subtilis FoF1-ATP synthase, a variant of CFP, and a variant of YFP. Large conformational changes 
of the subunit induced by ATP binding lead to an increase in the FRET signals (YFP/CFP ratio). To evaluate the 
ATP levels and dynamics of the Mt iPS cells, ATeam-iPS cells were generated via stable genomic integration of 
ATeam 1.03. ATeam 1.03 was cloned via the piggyBac vector by using an In-Fusion HD Cloning Kit (Takara, 
Kusatsu, Japan). The iPS cells on Matrigel-coated dishes were transfected with FuGENE HD (Promega, Madison, 
WI, USA) according to the manufacturer’s protocol. Drug selection was performed using 0.5 μg/ml puromycin 
(Sigma-Aldrich). The ATeam-iPS cells were cultured on puromycin-resistant SNL feeder cells generated using 
the pMXs-IP vector.
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Imaging and data analysis. Stable iPS cell lines were dissociated into single cells and plated on a 
glass-bottom dish (MatTek Corporation, Ashland, MA, USA). The iPS cells were washed with PBS and incubated 
in HBSS-based medium for 15 min. The HBSS medium was prepared according to the manufacturer’s instruc-
tions (Thermo Fisher Scientific), and 20 mM HEPES (Nacalai Tesque), 1 mM sodium pyruvate (Sigma-Aldrich), 
and 2 mM GlutaMax-1 (Thermo Fisher Scientific) were added. Ten minutes after monitoring began, 2DG 
(Sigma-Aldrich) or oligomycin A (Sigma-Aldrich) was injected manually. The final concentrations were 20 mM 
and 2 μM, respectively. Imaging analysis of single iPS cells was performed on a Nikon Ti-E-PFS inverted micro-
scope (Nikon, Tokyo, Japan) by using a dry objective (CFI Plan Apo λ 40 × NA 0.95; Nikon) and the follow-
ing filter sets (Semrock, Rochester, NY, USA) for dual-emission-ratio imaging of ATeam 1.03: 438/24, DM458, 
and 483/32 (CFP) and 542/27 (YFP). An ORCA-AG cooled charge-coupled device camera (Zyla4.2 sCMOS, 
Andor Technology, Belfast, UK) was used to capture fluorescence images. The microscope system was oper-
ated by NIS-Elements (Nikon). For the data analysis, regions of interest (ROIs) were selected in the cytosol. The 
YFP/CFP intensity ratio of the ROIs was calculated at every time point using MetaMorph (Molecular Devices, 
Sunnyvale, CA, USA).
Statistics. The results are expressed as the means ± SD or SE. Unless otherwise indicated, the statistical sig-
nificance of the differences in mean values among the four clones for each patient were assessed by analysis of 
variance (ANOVA) with a post hoc test (Tukey’s test) using Statcel2 Software (OMS Publishing, Saitama, Japan). 
P-values less than 0.05 were considered to indicate statistical significance and are indicated by asterisks in the 
figures.
Study approval. The studies presented here were approved by the Ethics Committees of Kyoto University 
and all methods were performed in accordance with the relevant guidelines and regulations. All patients provided 
written informed consent.
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